The Potential of Gene and Cell- Based Strategies for the Treatment of Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 492

[41] Ortolano S, Spuch C, Navarro C. Present and future of adeno

associated virus based gene therapy approaches. Recent Pat
Endocr Metab Immune Drug Discov 2012;6(1):47-66.

[61] Li H, Jiang X, Delaney J, Franceschetti T, Bilic-Curcic I,
Kalinovsky J, et al. Immature osteoblast lineage cells increase
osteoclastogenesis in osteogenesis imperfecta murine. Am J
Pathol 2010;176(5):2405-13.
[62] Otsu M, Sugamura K, Candotti F. In vivo competitive stud-
ies between normal and common gamma chain-defective bone
marrow cells: implications for gene therapy. Hum Gene Ther
2000;11(14):2051-6.
[63] Roberts C, Kean L, Archer D, Balkan C, Hsu LL. Murine and
math models for the level of stable mixed chimerism to cure
beta-thalassemia by nonmyeloablative bone marrow transplan-
tation. Ann N Y Acad Sci 2005;1054:423-8.
[64] Loefler BJ, Kellam JF, Sims SH, Bosse MJ. Prospective obser-
vational study of donor-site morbidity following anterior
iliac crest bone-grafting in orthopaedic trauma reconstruction
patients. J Bone Joint Surg Am 2012;94(18):1649-54.
[65] Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL,
Neel M, et al. Transplantability and therapeutic effects of bone
marrow-derived mesenchymal cells in children with osteogen-
esis imperfecta. Nat Med 1999;5(3):309-13.
[66] Horwitz EM, Prockop DJ, Gordon PL, Koo WW, Fitzpatrick LA,
Neel MD, et al. Clinical responses to bone marrow transplan-
tation in children with severe osteogenesis imperfecta. Blood
2001;97(5):1227-31.
[67] Kalajzic I, Kalajzic Z, Kaliterna M, Gronowicz G, Clark SH,
Lichtler AC, et al. Use of type I collagen green luorescent
protein transgenes to identify subpopulations of cells at dif-
ferent stages of the osteoblast lineage. J Bone Miner Res
2002;17(1):15-25.
[68] Bilic-Curcic I, Kronenberg M, Jiang X, Bellizzi J, Mina M,
Marijanovic I, et al. Visualizing levels of osteoblast differentia-
tion by a two-color promoter-GFP strategy: type I collagen-GFP-
cyan and osteocalcin-GFPtpz. Genesis 2005;43(2):87-98.
[69] Li S, Tu Q, Zhang J, Stein G, Lian J, Yang PS, et al. Systemically
transplanted bone marrow stromal cells contributing to bone tis-
sue regeneration. J Cell Physiol 2008;215(1):204-9.
[70] Matsumoto T, Mifune Y, Kawamoto A, Kuroda R, Shoji T,
Iwasaki H, et al. Fracture induced mobilization and incorpora-
tion of bone marrow-derived endothelial progenitor cells for
bone healing. J Cell Physiol 2008;215(1):234-42.
[71] Kumagai K, Vasanji A, Drazba JA, Butler RS, Muschler GF.
Circulating cells with osteogenic potential are physiologically
mobilized into the fracture healing site in the parabiotic mice
model. J Orthop Res 2008;26(2):165-75.
[72] Boban I, Jacquin C, Prior K, Barisic-Dujmovic T, Maye P, Clark
SH, et al. The 3.6 kb DNA fragment from the rat Col1a1 gene
promoter drives the expression of genes in both osteoblast and
osteoclast lineage cells. Bone 2006;39(6):1302-12.
[73] Dominici M, Marino R, Rasini V, Spano C, Paolucci P, Conte P,
et al. Donor cell-derived osteopoiesis originates from a self-
renewing stem cell with a limited regenerative contribution
after transplantation. Blood 2008;111(8):4386-91.
[74] Wang L, Liu Y, Kalajzic Z, Jiang X, Rowe DW. Heterogeneity of
engrafted bone-lining cells after systemic and local transplanta-
tion. Blood 2005;106(10):3650-7.
[75] Yu X, Wang L, Peng F, Jiang X, Xia Z, Huang J, et al. The effect
of fresh bone marrow cells on reconstruction of mouse calvarial
defect combined with calvarial osteoprogenitor cells and colla-
gen-apatite scaffold. J Tissue Eng Regen Med. 2012 Mar 31. doi:
10.1002/term.1490. [Epub ahead of print] PMID: 22473786.

[42] Boban I, Barisic-Dujmovic T, Clark SH. Parabiosis model does

not show presence of circulating osteoprogenitor cells. Genesis
2010;48(3):171-82.

[43] Huang S, Kamihira M. Development of hybrid viral vectors for

gene therapy. Biotechnol Adv 2013;31(2):208-23.

[44] Hackett PB, Largaespada DA, Switzer KC, Cooper LJ.

Evaluating risks of insertional mutagenesis by DNA transpo-
sons in gene therapy. Transl Res 2013;161(4):265-83.

[45] Peace BE, Florer JB, Witte D, Smicun Y, Toudjarska I, Wu G,

et al. Endogenously expressed multimeric self-cleaving ham-
merhead ribozymes ablate mutant collagen in cellulo. Mol Ther
2005;12(1):128-36.

[46] Fortes P, Cuevas Y, Guan F, Liu P, Pentlicky S, Jung SP, et al.

Inhibiting expression of speciic genes in mammalian cells with 5′
end-mutated U1 small nuclear RNAs targeted to terminal exons of
pre-mRNA. Proc Natl Acad Sci USA 2003;100(14):8264-9.

[47] Lindahl K, Rubin CJ, Kindmark A, Ljunggren O. Allele depen-

dent silencing of COL1A2 using small interfering RNAs. Int J
Med Sci 2008;5(6):361-5.

[48] Chamberlain JR, Schwarze U, Wang PR, Hirata RK, Hankenson

KD, Pace JM, et al. Gene targeting in stem cells from individuals
with osteogenesis imperfecta. Science 2004;303(5661):1198-201.

[49] Chamberlain JR, Deyle DR, Schwarze U, Wang P, Hirata RK,

Li Y, et al. Gene targeting of mutant COL1A2 alleles in mesen-
chymal stem cells from individuals with osteogenesis imper-
fecta. Mol Ther 2008;16(1):187-93.

[50] Prieto J, Molina R, Montoya G. Molecular scissors for in situ cel-

lular repair. Crit Rev Biochem Mol Biol 2012;47(3):207-21.

[51] Kass EM, Jasin M. Collaboration and competition between

DNA double-strand break repair pathways. FEBS Lett 2010;
584(17):3703-8.

[52] Remy S, Tesson L, Menoret S, Usal C, Scharenberg AM, Anegon I.

Zinc-inger nucleases: a powerful tool for genetic engineering of
animals. Transgenic Res 2010;19(3):363-71.

[53] Handel EM, Cathomen T. Zinc-inger nuclease based genome sur-

gery: it's all about speciicity. Curr Gene Ther 2011;11(1):28-37.

[54] Gabriel R, Lombardo A, Arens A, Miller JC, Genovese P,

Kaeppel C, et al. An unbiased genome-wide analysis of zinc-
inger nuclease speciicity. Nat Biotechnol 2011;29(9):816-23.

[55] Bedell VM, Wang Y, Campbell JM, Poshusta TL, Starker CG,

Krug II RG, et al. In vivo genome editing using a high-eficiency
TALEN system. Nature 2012;491(7422):114-8.

[56] Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C,

et al. Eficient design and assembly of custom TALEN and other
TAL effector-based constructs for DNA targeting. Nucleic Acids
Res 2011;39(12):e82.

[57] Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al.

RNA-guided human genome engineering via Cas9. Science
2013;339(6121):823-6.

[58] Pyott SM, Pepin MG, Schwarze U, Yang K, Smith G, Byers PH.

Recurrence of perinatal lethal osteogenesis imperfecta in sib-
ships: parsing the risk between parental mosaicism for domi-
nant mutations and autosomal recessive inheritance. Genet Med
2011;13(2):125-30.

[59] Cabral WA, Marini JC. High proportion of mutant osteoblasts is

compatible with normal skeletal function in mosaic carriers of
osteogenesis imperfecta. Am J Hum Genet 2004;74(4):752-60.

[60] Uveges TE, Collin-Osdoby P, Cabral WA, Ledgard F, Goldberg L,

Bergwitz C, et al. Cellular mechanism of decreased bone in Brtl
mouse model of OI: imbalance of decreased osteoblast function
and increased osteoclasts and their precursors. J Bone Miner Res
2008;23(12):1983-94.

[76] Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall

RY, et al. Isolated allogeneic bone marrow-derived mesenchy-
mal cells engraft and stimulate growth in children with osteo-
genesis imperfecta: implications for cell therapy of bone. Proc
Natl Acad Sci USA 2002;99(13):8932-7.